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Abstract: Review on CDCP1, with data on DNA/RNA, on the protein encoded and where the gene is implicated. 
 
Identity 
Other names: CD318, SIMA135, TRASK 
HGNC (Hugo): CDCP1 
Location: 3p21.31 
DNA/RNA 
Note 
CDCP1 (CUB Domain Containing Protein) was 
independently identified by several research groups. 
CDCP1 was initially isolated as a gene expressed in 
colorectal cancer (Scherl-Mostageer et al.,2001). The 
CDCP1 gene product was independently identified as a 
protein phosphorylated during mitosis and cellular 
detachment by Src kinases (Bhatt et al., 2005) and it is 
also known as Trask (Transmembrane and Associated 
with Src Kinases). 
Description 
The CDCP1 gene comprises 9 verified exons. 
Transcription 
Two alternative transcripts have been described (Perry 
et al., 2007).  
The full length transcript (isoform 1) is approximately 
6.4 kb in length, spans all 9 exons and encodes a 
transmembrane protein. The isoform 2 transcript is 1.4 
kb in length, contains the first four 5'exons of the 
CDCP1 gene. The isoform 2 transcript continues from 
the exon 4 end into the adjacent intron, where it 
terminates shortly at an alternative polyadenylation 
signal, giving rise to a truncated transcript (Perry et al.,  
2007). The isoform 2 encodes a truncated, secreted 
protein of 343 amino acids, that contains the N-
terminal part of the extracellular domain (and one CUB 
domain) of CDCP1 and lacks the transmembrane and 
intracellular modules. Currently, most studies have 
been focused on the more prominently expressed 
isoform 1.  
The function and expression of isoform 2 remains 
poorly understood. 
Pseudogene 
No pseudogenes, related to CDCP1 are present in the 
human genome. 
Protein 
Note 
The full-length CDCP1 protein consists of 836 amino 
acids. The SDS PAGE migration of CDCP1 protein is 
approximately 140 kDa, which differs from its 
calculated molecular weight (approximately 90 kDa) 
due to extensive glycosylation (Bhatt et al., 2005).  
CDCP1 is cleaved by serine proteases at the 
extracellular domain next to Arg368 to generate a 
truncated molecule of 80 kDa size (Bhatt et al., 2005) 
(in some cases it is referred as 70kDa). Different cell 
lines express different amounts of p140 and p80, 
depending on the activity of endogenous serine 
proteases (Spassov et al., 2012). In vivo, CDCP1 is not 
cleaved during normal physiological circumstances, but 
its cleavage can be induced during tumorigenesis or 
tissue injury. (Spassov et al., 2011; Spassov et al., 
2013). 
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CDCP1 contains a signal peptide and a transmembrane region for proper membrane localization. The larger extracellular domain 
contains two or three CUB domains. The triangles indicate the naturally occurring cleavage sites after the signal peptide and at Arg368 of 
the extracellular domain. Abbreviations indicate the signal peptide (SP), CUB domains, transmembrane region (TM), proline-rich region 
(PRR). The intracellular domain contains 5 tyrosine residues (indicated by Y) all of which can be specifically phosphorylated by Src family 
kinases. 
 
Description 
The full-length CDCP1 protein is a type I 
transmembrane protein. The proper membrane 
localization is ensured by the presence of a signal 
peptide and a transmembrane domain (Bhatt et al., 
2005).  
The extracellular region is large and it is reported to 
contain two or three CUB domains. This difference 
arises because one of the Cub domains has a very weak 
degree of homology and may not be recognized readily 
as a Cub domain depending on the software used.  
The CUB (Complement protein components C1, 
Urchin embryonic growth factor and Bone 
morphogenic protein 1) domains are characterized by 
immunoglobulin-like folds and are involved in protein-
protein interactions and are found in functionally 
diverse, mostly developmentally regulated proteins and 
in peptidases. The intracellular domain of CDCP1 
contains five tyrosine residues - Y707, Y734, Y743, 
Y762 and Y806. Phosphorylation of CDCP1 is 
exclusively mediated by Src kinases (Bhatt et al., 
2005). 
Expression 
CDCP1 is predominantly expressed in epithelial tissues 
and its expression is not detectable in fibroblasts and 
other mesenchymal cells (Spassov et al., 2009). CDCP1 
also has been reported to be expressed in hematopoietic 
progenitor cells but not in mature blood cell types 
(Bühring et al., 2004). 
Localisation 
CDCP1 is a transmembrane protein and is located on 
the cell membrane. 
Function 
CDCP1, when phosphorylated, functions to inhibit 
integrin signaling, disrupt focal adhesions and oppose 
cell adhesion (Spassov et al., 2011). Phosphorylation of 
CDCP1 depends on the adherence state of the cells 
(Spassov et al., 2009). The loss of anchorage or cellular 
detachment is associated with the phosphorylation of 
CDCP1 as well as the concomitant dephosphorylation 
of focal adhesion proteins, consistent with the 
dismantling of focal adhesions (Spassov et al., 2011). 
Contrary, during cellular attachment CDCP1 is 
dephosphorylated, allowing the phosphorylation of 
focal adhesion proteins. Knockdown of CDCP1 leads 
to increased adhesiveness and experimentally induced 
over-expression and phosphorylation of CDCP1 
decreases cell adhesion and leads to cell rounding and a 
detached phenotype (Spassov et al., 2011). CDCP1 
regulates cellular migration and both loss of function 
and gain of functions of CDCP1 can lead to inhibition 
of migration (Spassov et al., 2011). The knockdown of 
CDCP1 leads to permanent cell attachment to 
substratum, while its excessive phosphorylation inhibits 
cell spreading and cell motility. The anti-adhesion and 
anti-migratory functions of CDCP1 are mediated 
through negative regulation on integrin receptors 
(Spassov et al., 2011). When phosphorylated by Src 
kinases, CDCP1 appears in complexes containing β1 
integrin, interfering with integrin clustering and 
preventing the mechanical and signaling events that 
link the intracellular cytoskeleton with the extracellular 
matrix. This is mediated through the inhibition of 
integrin clustering without affecting integrin affinity 
state or ligand binding activity (Spassov et al., 2011). 
Homology 
The human genome does not contain other genes 
related to CDCP1. The degree of homology within the 
CUB domains of other proteins is low (maximum 20% 
identity). More importantly other CUB domain 
containing proteins do not contain the intracellular 
module that is regulated and phosphorylated by Src 
kinases. This indicates that there is no other related 
gene in the human genome that may play a redundant 
role with CDCP1. CDCP1 homologs are present only 
in the vertebrate species, including zebra fish, Xenopus, 
chicken and mammals. CDCP1 is not present in 
invertebrates and lower organisms. 
Mutations 
Note 
CDCP1 is localized on chromosomal region (3p21.31), 
which is very frequently deleted in human cancers (Ji et 
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al., 2005). LOH of CDCP1 is frequent (90-100%) in 
lung cancers and has been observed in breast cancers 
and other cancer types. 
Germinal 
Germinal mutations associated with disease have not 
been described yet. Several polymorphic sites are 
described in the gene databases. The role of these 
polymorphic sites is currently unknown. 
Somatic 
Somatic mutations in cancer are infrequent. According 
to COSMIC database (http://cancer.sanger.ac.uk) 
currently (June 2013) 38 somatic cancer mutations 
have been identified from 7080 tumor samples (0.5%). 
Some cancer types show somewhat elevated mutational 
frequency; for instance 2.4% in melanoma and 1.4 % in 
colon cancer. It is unclear at this moment if these 
mutations have functional significance or represent 
passenger mutations. 
Implicated in 
Tumorigenesis 
Note 
Expression and phosphorylation in tumors 
The expression of CDCP1 relative to the normal 
epithelium is reduced or lost in some tumors, 
particularly in breast, colon, prostate and lung cancers 
(Wong et al., 2009; Spassov et al., 2012). This is due to 
loss of heterozygosity in CDCP1 genomic region 
and/or promoter methylation (Spassov et al., 2012). 
CDCP1 is widely and abundantly expressed in human 
epithelial tissues, but its phosphorylation is not 
detectable in normally anchored epithelial layers 
(Spassov et al., 2009). However, phosphorylation of 
CDCP1 is seen in many epithelial tumors from all 
stages including early stage carcinomas, invasive, and 
metastatic tumors (Wong et al., 2009). The 
phosphorylation of CDCP1 in tumors suggests that they 
may exist at an abnormal or deficient state of 
anchorage in vivo (Spassov et al., 2011). This may be 
due to abnormalities in the composition of the 
surrounding matrix, defective assembly of adhesion 
complexes, or defective signaling through the integrin 
adhesion complex. Specifically, this may be due to the 
absence of a continuous basal lamina which typically 
underlies the basal surface of epithelial cells in the 
normal epithelium but is highly abnormal or missing in 
epithelial tumors. 
Animal model  
Mice lacking CDCP1 do not exhibit gross morphologic, 
reproductive or behavioral abnormalities compared 
with wild-type mice, and histologic examination of 
multiple organ systems found no significant pathology 
and no observed histologic differences (Spassov et al., 
2013). Mammary tumors driven by the PyMT 
oncogene and skin tumors driven by activation of 
Hedgehog pathway developed with accelerated kinetics 
in CDCP1 null mice, establishing a tumor suppressing 
function for this gene during cancer initiation and 
evolution (Spassov et al., 2013). Mechanistic 
investigations in mammary tumor cell lines derived 
from CDCP1-deficient mice revealed a de-repression of 
integrin signaling and an enhancement of integrin-
growth factor receptor cross-talk; hence increased 
growth factor signaling and cell proliferation of 
CDCP1 null cancer cells (Spassov et al., 2013). 
Metastasis 
The role of CDCP1 in cellular migration may suggest a 
potential role of this gene in cancer metastasis. 
However, this role may be a complex one, considering 
that both loss of function and gain of function of 
CDCP1 inhibit migratory capacity of the cells. 
Inducible expression and phosphorylation of CDCP1 in 
breast cancer MCF7 cell line decreased the number of 
lymph node metastasis after orthotopic mammary fat 
pad implantation (Spassov et al., 2012). Similarly, the 
inducible expression of CDCP1 in v-src transformed 
NIH3T3 cells significantly decreased the lung 
colonization capacity of the cells after tail vein 
inoculation (Spassov et al., 2012). Knockdown of 
CDCP1 have also been reported to decrease 
experimental metastasis of lung and melanoma cell 
lines (Uekita et al., 2007; Liu et al., 2011). Future work 
is required to elucidate the functions of CDCP1 in 
cancer metastasis and whether there will be clinical 
benefits of targeting this gene. Several efforts have 
been made to target CDCP1 with monoclonal antibody 
that recognizes the extracellular domain of the protein. 
Such antibodies induce the phosphorylation of CDCP1 
and have been shown to suppress experimental 
metastasis in preclinical models (Siva at al., 2008; 
Casar et al., 2012). It is unclear if this is due to effects 
on CDCP1 function or if it is mediated through 
immunological mechanisms. 
Hybrid/Mutated gene 
No hybrid genes, containing CDCP1 are known. 
Abnormal protein 
No fusions with CDCP1 have been reported. 
Oncogenesis 
CDCP1 null mice show accelerated oncogenesis in 
genetically modified experimental models of skin and 
breast cancers. 
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